These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

685 related articles for article (PubMed ID: 18390969)

  • 1. Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Société Francaise de Greffe de Moëlle et de Thérapie Cellulaire.
    Le Gouill S; Milpied N; Buzyn A; De Latour RP; Vernant JP; Mohty M; Moles MP; Bouabdallah K; Bulabois CE; Dupuis J; Rio B; Gratecos N; Yakoub-Agha I; Attal M; Tournilhac O; Decaudin D; Bourhis JH; Blaise D; Volteau C; Michallet M;
    J Clin Oncol; 2008 May; 26(14):2264-71. PubMed ID: 18390969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low nonrelapse mortality and prolonged long-term survival after reduced-intensity allogeneic stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma: report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
    Sirvent A; Dhedin N; Michallet M; Mounier N; Faucher C; Yakoub-Agha I; Mohty M; Robin M; Tabrizi R; Clement L; Bilger K; Larosa F; Contentin N; Huyn A; François S; Bulabois CE; Ceballos P; Bourrhis JH; Buzyn A; Cornillon J; Guillerm G; de Revel T; Bay JO; Guilhot F; Milpied N
    Biol Blood Marrow Transplant; 2010 Jan; 16(1):78-85. PubMed ID: 19744569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
    Michallet M; Le QH; Mohty M; Prébet T; Nicolini F; Boiron JM; Esperou H; Attal M; Milpied N; Lioure B; Bordigoni P; Yakoub-Agha I; Bourhis JH; Rio B; Deconinck E; Renaud M; Chir Z; Blaise D
    Exp Hematol; 2008 May; 36(5):535-44. PubMed ID: 18346838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).
    Robin M; Tabrizi R; Mohty M; Furst S; Michallet M; Bay JO; Cahn JY; De Coninck E; Dhedin N; Bernard M; Rio B; Buzyn A; Huynh A; Bilger K; Bordigoni P; Contentin N; Porcher R; Socié G; Milpied N
    Br J Haematol; 2011 Feb; 152(3):331-9. PubMed ID: 21133885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allogeneic bone marrow transplantation for chronic myeloid leukemia in childhood: a report from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).
    Millot F; Esperou H; Bordigoni P; Dalle JH; Michallet M; Michel G; Bourhis JL; Kuenz M; Blaise D; Garban F; Plouvier E; Rome A; Guilhot J; Guilhot F
    Bone Marrow Transplant; 2003 Nov; 32(10):993-9. PubMed ID: 14595387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
    Kuruvilla J; Shepherd JD; Sutherland HJ; Nevill TJ; Nitta J; Le A; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Toze CL; Smith CA; Barnett MJ; Song KW
    Biol Blood Marrow Transplant; 2007 Aug; 13(8):925-31. PubMed ID: 17640596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antithymocyte globulins and chronic graft-vs-host disease after myeloablative allogeneic stem cell transplantation from HLA-matched unrelated donors: a report from the Sociéte Française de Greffe de Moelle et de Thérapie Cellulaire.
    Mohty M; Labopin M; Balère ML; Socié G; Milpied N; Tabrizi R; Ifrah N; Hicheri Y; Dhedin N; Michallet M; Buzyn A; Cahn JY; Bourhis JH; Blaise D; Raffoux C; Espérou H; Yakoub-Agha I
    Leukemia; 2010 Nov; 24(11):1867-74. PubMed ID: 20882046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allogeneic stem cell transplantation for peripheral T cell lymphomas: a retrospective study in 285 patients from the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).
    Mamez AC; Dupont A; Blaise D; Chevallier P; Forcade E; Ceballos P; Mohty M; Suarez F; Beguin Y; Peffault De Latour R; Rubio MT; Tournilhac O; Nguyen S
    J Hematol Oncol; 2020 May; 13(1):56. PubMed ID: 32429979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation.
    Cook G; Smith GM; Kirkland K; Lee J; Pearce R; Thomson K; Morris E; Orchard K; Rule S; Russell N; Craddock C; Marks DI;
    Biol Blood Marrow Transplant; 2010 Oct; 16(10):1419-27. PubMed ID: 20399879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
    Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation.
    Kyriakou C; Canals C; Finke J; Kobbe G; Harousseau JL; Kolb HJ; Novitzky N; Goldstone AH; Sureda A; Schmitz N
    J Clin Oncol; 2009 Aug; 27(24):3951-8. PubMed ID: 19620487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells.
    Corradini P; Dodero A; Zallio F; Caracciolo D; Casini M; Bregni M; Narni F; Patriarca F; Boccadoro M; Benedetti F; Rambaldi A; Gianni AM; Tarella C
    J Clin Oncol; 2004 Jun; 22(11):2172-6. PubMed ID: 15169805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
    Kim HJ; Min WS; Cho BS; Eom KS; Kim YJ; Min CK; Lee S; Cho SG; Jin JY; Lee JW; Kim CC
    Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma.
    Doocey RT; Toze CL; Connors JM; Nevill TJ; Gascoyne RD; Barnett MJ; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Shepherd JD; Sutherland HJ; Voss NJ; Smith CA; Song KW
    Br J Haematol; 2005 Oct; 131(2):223-30. PubMed ID: 16197454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allogeneic haematopoietic stem cell transplantation as a promising treatment for natural killer-cell neoplasms.
    Murashige N; Kami M; Kishi Y; Kim SW; Takeuchi M; Matsue K; Kanda Y; Hirokawa M; Kawabata Y; Matsumura T; Kusumi E; Hirabayashi N; Nagafuji K; Suzuki R; Takeuchi K; Oshimi K
    Br J Haematol; 2005 Aug; 130(4):561-7. PubMed ID: 16098071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: complete response at transplant predicts survival.
    Kim MK; Kim S; Lee SS; Sym SJ; Lee DH; Jang S; Park CJ; Chi HS; Huh J; Suh C
    Ann Hematol; 2007 Jun; 86(6):435-42. PubMed ID: 17256144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
    Sureda A; Robinson S; Canals C; Carella AM; Boogaerts MA; Caballero D; Hunter AE; Kanz L; Slavin S; Cornelissen JJ; Gramatzki M; Niederwieser D; Russell NH; Schmitz N
    J Clin Oncol; 2008 Jan; 26(3):455-62. PubMed ID: 18086796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy.
    Yakoub-Agha I; Mesnil F; Kuentz M; Boiron JM; Ifrah N; Milpied N; Chehata S; Esperou H; Vernant JP; Michallet M; Buzyn A; Gratecos N; Cahn JY; Bourhis JH; Chir Z; Raffoux C; Socié G; Golmard JL; Jouet JP;
    J Clin Oncol; 2006 Dec; 24(36):5695-702. PubMed ID: 17116940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical relevance of three subtypes of primary sinonasal lymphoma characterized by immunophenotypic analysis.
    Kim GE; Koom WS; Yang WI; Lee SW; Keum KC; Lee CG; Suh CO; Hahn JS; Roh JK; Kim JH
    Head Neck; 2004 Jul; 26(7):584-93. PubMed ID: 15229900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic stem cell transplantation for chronic myelomonocytic leukemia: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire.
    Park S; Labopin M; Yakoub-Agha I; Delaunay J; Dhedin N; Deconinck E; Michallet M; Robin M; De Revel T; Bernard M; Vey N; Lioure B; Lapusan S; Tabrizi R; Bourhis JH; Huynh A; Beguin Y; Socié G; Dreyfus F; Fenaux P; Mohty M
    Eur J Haematol; 2013 May; 90(5):355-64. PubMed ID: 23320648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.